Cannabis After Coronary Stenting: Cardiovascular and Medication Safety Considerations

People who have a coronary stent often ask whether medical marijuana or other cannabis products are safe to use. The short answer is that there is no established cannabis treatment for coronary artery disease, and a stent does not eliminate the underlying risk of heart attack or other cardiovascular problems. Cannabis may also affect heart rate, blood pressure and the way some heart medications work.

A coronary stent is a small mesh tube placed inside a narrowed or blocked artery to help restore blood flow. After the procedure, patients commonly take aspirin plus a P2Y12 inhibitor such as clopidogrel, prasugrel or ticagrelor for a period determined by their cardiologist. These medications help prevent a clot from forming in or near the stent, so they should not be stopped or changed without medical advice.

What is known about cannabis and the heart?

The American Heart Association’s 2020 scientific statement on cannabis and cardiovascular health concluded that evidence remains limited and that important cardiovascular concerns exist. Cannabis—particularly products containing THC—can temporarily increase heart rate and may raise or lower blood pressure depending on the dose, the person’s tolerance and the circumstances of use. These changes can be more concerning in people with coronary artery disease or a history of a heart attack.

Inhaled cannabis presents additional concerns. Smoke contains many of the same irritants and toxic compounds found in tobacco smoke, and smoking can place added stress on the cardiovascular and respiratory systems. Vaporized products are not automatically risk-free, and long-term cardiovascular effects of different cannabis formulations and delivery methods remain uncertain. Edibles, tinctures and other noncombustible products avoid smoke, but they can produce delayed, unpredictable effects and may lead to accidental overuse.

Research has also reported associations between cannabis use and serious cardiovascular events, including arrhythmias and, in some studies, heart attack and stroke. Much of this evidence is observational, so it cannot establish that cannabis caused a particular event. Results are also affected by factors such as tobacco use, other drugs, underlying illness, product potency and route of administration. Nevertheless, patients with established cardiovascular disease should not assume that cannabis is harmless.

THC and CBD are not interchangeable

THC is the primary intoxicating compound in cannabis and is the component most clearly associated with short-term changes in heart rate, blood pressure and alertness. High-potency THC products may be especially difficult to dose safely.

CBD does not produce the same intoxicating effect as THC, but that does not make it risk-free or proven to protect the heart. Laboratory and animal studies have suggested possible anti-inflammatory, antioxidant or blood-vessel effects, while human evidence for treating coronary artery disease, arrhythmias or damage from a heart attack is insufficient. A 2020 review of CBD’s cardiovascular effects concluded that additional clinical research is needed before CBD can be recommended as a cardiovascular treatment.

Product labels may also be inaccurate, and products marketed as CBD may contain THC or other ingredients. The U.S. Food and Drug Administration warns that CBD can interact with other medicines and that most nonprescription CBD products have not been evaluated for safety, effectiveness or consistent quality.

Medication interactions may be the most important concern

Patients with coronary stents may be taking several medications, including antiplatelet drugs, statins, blood-pressure medicines and, in some cases, anticoagulants. Cannabis and cannabinoids can affect liver enzymes and drug transport systems involved in medication metabolism.

CBD may inhibit CYP2C19, an enzyme involved in converting clopidogrel into its active form. The clinical importance of this interaction has not been established in well-designed trials, but it raises a theoretical concern that clopidogrel may not work as intended. This is particularly important after stenting, when inadequate platelet inhibition could increase the risk of a clot. Patients should not switch, skip or double doses of clopidogrel—or substitute another antiplatelet drug—without speaking with their cardiologist.

Evidence for an interaction between cannabis and warfarin is limited but more direct: case reports have described elevated INR levels and bleeding after cannabis or CBD use. A 2023 systematic review found very low-quality evidence supporting a possible interaction with warfarin and emphasized the need for careful monitoring. Evidence for interactions with newer anticoagulants and other cardiovascular drugs is less clear.

What patients with stents should do

• Tell every clinician and pharmacist about cannabis use. Include THC, CBD, medical marijuana, recreational cannabis, edibles, tinctures, vapes and topical products.
• Do not stop antiplatelet therapy. Follow the medication plan prescribed after stenting, even if you feel well.
• Ask for a medication review before starting or changing a cannabis product. The risk may depend on the product’s THC and CBD content, dose, frequency and route.
• Avoid smoking cannabis. No cannabis route has been proven safe for people with coronary artery disease, and noncombustible products still carry dosing and interaction risks.
• Do not rely on cannabis to treat chest pain, shortness of breath, fatigue or an irregular heartbeat. These symptoms may signal a serious cardiovascular problem and require medical evaluation.

Seek emergency care for new or worsening chest pressure, pain spreading to the arm, jaw or back, severe shortness of breath, fainting, sudden weakness or a sustained racing or irregular heartbeat. Cannabis should be considered an additional medication exposure—not a substitute for antiplatelet therapy, cholesterol treatment, cardiac rehabilitation or other proven care.

For people with coronary stents, the safest decision is an individualized discussion with a cardiologist or pharmacist before using cannabis. Current evidence does not show that cannabis protects a stented artery, and the potential cardiovascular and medication-related risks deserve more weight than unsupported claims about particular strains or “heart-healthy” cannabinoids.